Expert consensus on pharmaceutical practice of fondaparinux sodium

Title: Expert consensus on pharmaceutical practice of fondaparinux sodium
Edition: Original
Classification: Experts consensus
Field: Treatment
Countries and regions: China
Guidelines users: Medicine and clinical pharmacy
Evidence classification method: GRADE classification system
Development unit: 中华医学会临床药学分会;四川省医学科学院&四川省人民医院
Registration time: 2022-11-19
Registration number: PREPARE-2022CN750
Purpose of the guideline: Thromboembolic disease is a kind of disease with high mortality and serious harm to human health. Anticoagulant therapy is the main treatment for thromboembolic disease. As a parenteral anticoagulant, fondaparinux sodium has caused many problems for medical workers due to the differences in indications at home and abroad and the lack of understanding of its application. There are irrational drug use and drug use beyond the instructions in clinical practice. Therefore, it is particularly important to strengthen the rational use of fondaparinux sodium.